Drug Profile
MB 107 - Mustang Bio
Alternative Names: CL20-4i-EF1alpha- HgammaC-OPT; CL20-i4-EF1α-hγc-OPT; Ex vivo gene therapy - Mustang Bio; Gene-modified CD34+ hematopoietic stem cells; IND-14570; Lentiviral genetherapy; MB 207; MB-107; MB-107 XSCID gene therapy; MB-117; MB-217; VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT; X-linked severe combined immunodeficiency gene therapy - Mustang Bio; XSCID gene therapyLatest Information Update: 07 Feb 2024
Price :
$50
*
At a glance
- Originator St. Jude Childrens Research Hospital
- Developer Mustang Bio; National Heart, Lung and Blood Institute; National Institute of Allergy and Infectious Diseases; National Institutes of Health Clinical Center; Seattle Children's Hospital; St. Jude Childrens Research Hospital; UCSF Benioff Childrens Hospital
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Severe combined immunodeficiency
Most Recent Events
- 30 Jan 2024 National Institute of Allergy and Infectious Diseases in collaboration with National Institutes of Health Clinical Center reinitiates the enrollment in a phase I/II clinical trial for Severe combined immunodeficiency (In children, In adolescents, In adults, Treatment-experienced) in USA (IV) (NCT01306019)
- 19 Apr 2023 St. Jude Children's Research Hospital suspends phase-I/II trial in Severe combined immunodeficiency (In neonates, In infants, Newly diagnosed) in USA (IV) (NCT01512888)
- 26 May 2022 National Institute of Allergy and Infectious Diseases in collaboration with National Institutes of Health Clinical Center suspends a phase I/II clinical trial in Severe combined immunodeficiency (In children, In adolescents, In adults, Treatment-experienced) in USA (IV) (NCT01306019)